Clinical Trial Detail

NCT ID NCT02711553
Title A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

biliary tract cancer

ampulla of Vater adenocarcinoma

gallbladder cancer

cholangiocarcinoma

Therapies

Ramucirumab

Merestinib

Cisplatin + Gemcitabine

Age Groups: adult

No variant requirements are available.